Home › NDC Lookup › Ingredients › Atacicept › 85052-0101-04
Trutakna atacicept 150 mg Injection, Solution, Carton of 4 Syringes — NDC 85052-0101-04 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 85052-0101-04: Trutakna atacicept 150 mg Injection, Solution, Carton of 4 Syringes

by Vera Therapeutics, Inc
Inner NDC 85052-101-01 on each glass syringe (1 injection, solution) inside this package 11-digit 85052-0101-01

This is a package of 4 syringes of Trutakna atacicept 150 mg Injection, Solution from Vera Therapeutics, Inc, first listed with the FDA Jul 2026 and currently FDA-listed. It is this product's only package size.

🏷️ FDA NDC (as labeled) 85052-101-04 billing pads the product segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Aug 20, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 85052-101-04 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
85052 labeler · 101 product · 04 package
Package marketed since
Jul 7, 2026
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC)
0385052101012 · on each glass syringe (1 injection, solution) (inner NDC 85052-101-01)
FDA record last changed
Aug 20, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 85052-101-04
Product NDC 85052-101
11-digit billing NDC 85052010104
NCPDP billing unit ML — per mL (volume)
RxCUI 2747237, 2747244
UNII K3D9A0ICQ3
UPC 0385052101012
Application # BLA761486
SPL Set ID 24aa29f6-ccff-45d3-89af-4d26e525cef8
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2026-07-07
Route SUBCUTANEOUS
Dosage form INJECTION, SOLUTION
Substance ATACICEPT
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 089157
GCN 59389
HICL code 051413
Ingredient (HICL) Atacicept-Vymj
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2M
Therapeutic class — specific (HIC3) Immunosuppressant - Mab And Fusion Proteins
FDB label name TRUTAKNA 150 MG/ML AUTOINJECT
FDB brand name Trutakna
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 089157
  • GCN: 59389
  • HICL (First Databank): 051413
  • RxCUI (RxNorm): 2747237
Why two NDCs? The FDA registers this code as 85052-101-04 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 85052-0101-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name TRUTAKNA 150 MG/ML AUTOINJECT Ingredient Atacicept-Vymj
📖 What it is MedlinePlus · NLM

Atacicept-vymj injection is used to reduce proteinuria (protein in the urine) in patients with primary immunglobulin A nephropathy (IgAN; a kidney disease where IgA deposits build up in the kidneys causing inflammation). Atacicept-vymj injection is in a class of medications called recombinant fusion glycoproteins. It works by reducing the production of IgA.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is used in adults with primary IgA nephropathy who are at risk of the disease getting worse. It helps reduce protein in the urine. It is not yet known whether it slows long-term...
  • Take the missed dose as soon as you can. Then go back to your weekly schedule, counting one week from the day you took the missed dose.
  • What happens if I miss a dose of Atacicept?
  • Take the autoinjector out of the fridge and let it sit 15 to 30 minutes at room temperature. Do not warm it with heat. Inject under the skin of your abdomen or thigh, and use a dif...
📖 Read our full Atacicept guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
85052-0101-04 You're viewing this Main listing 4 SYRINGE, GLASS in 1 CARTON / 1 INJECTION, SOLUTION in 1 SYRINGE, GLASS Inner NDC 85052-101-01 · each glass syringe (1 injection, solution) 2026-07-07 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Trutakna 150 mgthis 85052-0101-04 Vera 4 syringes — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2026
First FDA approval
Jul 2026
📍
2026
Currently FDA-listed
listed with the FDA
🛡️
2038
Latest patent/protection listed
not a guaranteed launch date
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Jul 2038. This may affect when biosimilars become widely available, but it is not a guaranteed launch date.
📅 FDA approved Jul 7, 2026 ⏳ ~11.6 yr to latest listed protection

Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.

FDA Purple Book — biosimilars & interchangeables ⓘ
Reference product
🔒 No FDA-licensed biosimilars or interchangeable biosimilars are listed yet for this biologic. It currently has no biosimilar competition in the FDA Purple Book.
Source: FDA Purple Book (purplebooksearch.fda.gov), matched on the reference product’s active ingredient.
Patents & exclusivity — FDA Purple Book
Exclusivity RefProduct
2026 2028 2030 2032 2034 2036 2038
Today
LOE
Biologic patent Exclusivity
🏛️Reference-product exclusivity
A flat 12 years of FDA market protection from first licensure. No biosimilar can be licensed before it ends — regardless of patents.
🧪Listed biologic patents
Patents the reference maker lists covering the molecule, formulation, or manufacturing. A biosimilar generally can’t launch until these resolve.
🔁Interchangeability
An interchangeable biosimilar may be substituted at the pharmacy (state laws vary). The first one can earn its own exclusivity period.
🛈 What do these terms mean?
Biologic patent
A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
Reference-product exclusivity
A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
Interchangeable exclusivity
The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
Earliest biosimilar (LOE)
The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.

Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.

FDA exclusivity
CodeWhat it grantsExpires
RefProductReference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this dateJul 7, 2038
Common questions
Is there a biosimilar for TRUTAKNA 150 MG/ML AUTOINJECT?
No FDA-licensed biosimilar is currently listed for this biologic in the FDA Purple Book.
Why do different websites show different biosimilar dates?
Biosimilar availability isn’t based on one single date. Some sources use the reference-product exclusivity, some use the last listed patent, and patent litigation, settlements, and licenses can all change the real-world launch date. This page shows the underlying Purple Book dates so you can see why estimates differ.
Can a biosimilar launch before the last patent expires?
Sometimes. A biosimilar maker may settle with the reference manufacturer or receive a license to launch earlier. In other cases, the last listed protection delays competition.
What does “current Purple Book estimate” mean?
It means we’re using the latest patent and exclusivity dates currently listed in the FDA Purple Book. It is not a guaranteed launch date.
What does “FDA listed” mean?
It means the product appears in the FDA’s official directory. That’s a good sign a product exists for the U.S. market, but on its own it does not confirm a pharmacy can get it today. Where we have recent retail pricing data, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Purple Book for a patent or exclusivity on the reference biologic. It can affect when a biosimilar becomes widely available — but it is not a guaranteed launch date. Settlements and licenses can move the real date earlier or later.
Built from the FDA Purple Book Patent List (patents the reference-product sponsor has publicly listed under the BPCIA) plus reference-product exclusivity. Biosimilars cannot launch until these clear; patent litigation and settlements can shift the real date. Biologics have no small-molecule generics — competition comes from FDA-licensed biosimilars, not the Orange Book.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Atacicept inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerVera Therapeutics, Inc
FDA applicationBLA761486 (BLA)
Labeler code85052
First marketedJul 2026
Product typeHuman Prescription Drug
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 158 words ▾

1 INDICATIONS AND USAGE TRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. TRUTAKNA is a B-lymphocyte stimulator (BLyS)-specific inhibitor and A Proliferation Inducing Ligand (APRIL) blocker indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. ( 1 ).

This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

⏱️ Dosage and Administration ~1 min read ▾

2 DOSAGE AND ADMINISTRATION 150 mg once weekly by subcutaneous injection. ( 2.2 )

2.1Recommended Dosage The recommended dosage of TRUTAKNA is 150 mg injected subcutaneously (SC) once weekly. Missed Doses If a dose is missed, administer the missed dose as soon as possible and then resume once weekly dosing thereafter, one week from administration of the missed dose.

2.2Preparation and Administration Instructions TRUTAKNA autoinjector is intended for SC administration by patients/caregivers at home. The TRUTAKNA “Instructions for Use” contains more detailed instructions on the preparation and administration of TRUTAKNA [see Instructions for Use ] . Remove TRUTAKNA autoinjector from the refrigerator and allow it to sit for 15 to 30 minutes at room temperature between 15°C to 25°C (60°F to 77°F) prior to injecting.

Do not use an external heat source to heat TRUTAKNA, because heat may damage the product. If needed, TRUTAKNA autoinjector may be stored at room temperature up to 25°C (77°F), for a single period of 3 days (72 hours). Once TRUTAKNA has been stored at room temperature, it should not be placed back into the refrigerator.

Discard the autoinjector if not used within this 72‑hour period. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. TRUTAKNA should appear as a clear to slightly opalescent, brownish-yellow solution.

Do not use if the liquid contains particles or is cloudy. Administer each injection at a different location than the previous injection. Sites for injections include the abdomen and thigh.

💊 Dosage Forms and Strengths 40 words ▾

3 DOSAGE FORMS AND STRENGTHS TRUTAKNA is a clear to slightly opalescent, brownish-yellow solution, free of visible particles, available as follows: Injection: 150 mg/mL in a single-dose pre-filled autoinjector Injection: 150 mg/mL in a single-dose pre-filled autoinjector. ( 3 )

⛔ Contraindications 29 words ▾

4 CONTRAINDICATIONS TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA. Serious hypersensitivity to any of the ingredients in TRUTAKNA. ( 4 )

⚠️ Warnings and Cautions ~1 min read ▾

5 WARNINGS AND PRECAUTIONS Immunosuppression and Increased Risk of Infections: Delay initiation of TRUTAKNA during an active infection. During treatment, monitor for signs and symptoms of infections and consider interrupting TRUTAKNA if the infection becomes serious. ( 5.1 ) Immunosuppression and Immunization Risks : Live vaccines not recommended within 30 days prior to initiation of TRUTAKNA or during treatment. ( 5.2 )

5.1Immunosuppression and Increased Risk of Infections TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with a chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of patients in the TRUTAKNA group compared with 28% of participants in the placebo group [ see Adverse Reactions ( 6.1 ) ].

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. During treatment, monitor patients for signs and symptoms of infection.

If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled. The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

5.2Immunosuppression and Immunization Risks TRUTAKNA may interfere with the immune responses to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age appropriate immunizations according to current immunization guidelines. Live vaccines are not recommended within 30 days prior to initiation of TRUTAKNA or during treatment with TRUTAKNA as safety of coadministration has not been established.

🤒 Adverse Reactions ~1 min read ▾

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Immunosuppression and Increased Risk of Infections [see Warnings and Precautions ( 5.1 )] Immunosuppression and Immunization Risks [see Warnings and Precautions ( 5.2 )] The most common adverse reactions with TRUTAKNA (incidence ≥5% and greater than placebo) were upper respiratory tract infection, injection site reaction and injection site erythema. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vera Therapeutics at 1-833-633-8372 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of TRUTAKNA was evaluated in a randomized, double-blind, placebo-controlled clinical study in 428 adults with IgAN (Origin 3). The median duration of exposure was 34 weeks in the 214 patients treated with TRUTAKNA and 31 weeks in the 214 patients administered placebo [see Clinical Studies ( 14 )] .

The most common adverse reactions (reported in ≥5% of patients treated with TRUTAKNA and at a higher incidence than placebo) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs. 28%) and local administration reactions (30% vs. 5%).

The most common infection was upper respiratory tract infection (12% vs. 9%), and the most common local administration reactions were injection site reaction (19% vs. 2%) and injection site erythema (6% vs.

1%). Most adverse reactions observed in the TRUTAKNA group were mild or moderate in severity and resolved without treatment interruption or discontinuation.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary Available data on TRUTAKNA use in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant [see Warnings and Precautions ( 5.1 and 5.2 ), Clinical Pharmacology ( 12.1 ) and Clinical Considerations ] . There are risks to the mother and infant with untreated IgAN nephropathy in pregnancy (see Clinical Considerations ) .

In animal reproduction studies, no treatment-related malformations were observed in mice and rabbits at atacicept-vymj exposures approximately up to 12 times and 4 times, respectively, the clinical exposure at the recommended human dose (RHD) (see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnant women exposed to TRUTAKNA, or their healthcare providers, should report TRUTAKNA exposure by calling 1-833-633-8372. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk IgAN in pregnancy is associated with adverse maternal outcomes, including increased rates of cesarean section, pregnancy-induced hypertension, pre-eclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including stillbirth and low birth weight.

Fetal/Neonatal Adverse Reactions Based on mechanism of action, TRUTAKNA may cause immunosuppression in the in utero exposed infant. The potential clinical impact of TRUTAKNA exposure in infants exposed in utero should be considered. Data Animal Data In pregnant mice, SC administration of atacicept-vymj once every two days (0, 5, 20, and 80 mg/kg) throughout organogenesis from gestation day (GD) 6 to 15 did not result in any adverse effects on embryofetal development at up to 80 mg/kg, approximately 12 times the clinical exposure at the RHD based on area under the concentration curve (AUC).

In pregnant rabbits, SC administration of atacicept-vymj once every two days (0, 5, 20, and 80 mg/kg) throughout organogenesis from GD 6 to 18 resulted in early and late resorptions, reduced number of live fetuses, and decreased mean fetal weight at ≥20 mg/kg, doses that resulted in maternal toxicity (reduced body weight gain). Exposures at these doses were ≥4 times the clinical exposure at the RHD, based on AUC. Embryofetal malformations (enlarged bregmatic fontanella, severe reduction of ossification of parietal or frontal bones, and unossified interparietal bones) were observed at 80 mg/kg (maternally toxic dose), approximately 11 times the clinical exposure at the RHD, based on AUC.

No treatment-related malformations were observed at up to 20 mg/kg, approximately 4 times the clinical exposure at the RHD, based on AUC. In a pre- and post-natal development study in mice, SC administration of atacicept-vymj once every two days (0, 5, 20, or 80 mg/kg) throughout pregnancy and lactation (GD 6 to lactation day 21) did not result in adverse effects on maternal function or development of offspring at up to 80 mg/kg, approximately 12 times the clinical exposure at the RHD based on AUC.

8.2Lactation Risk Summary There are no data regarding the presence of atacicept-vymj in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TRUTAKNA and any potential adverse effects on the breastfed child from TRUTAKNA or from the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of TRUTAKNA… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary Available data on TRUTAKNA use in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant [see Warnings and Precautions ( 5.1 and 5.2 ), Clinical Pharmacology ( 12.1 ) and Clinical Considerations ] . There are risks to the mother and infant with untreated IgAN nephropathy in pregnancy (see Clinical Considerations ) .

In animal reproduction studies, no treatment-related malformations were observed in mice and rabbits at atacicept-vymj exposures approximately up to 12 times and 4 times, respectively, the clinical exposure at the recommended human dose (RHD) (see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnant women exposed to TRUTAKNA, or their healthcare providers, should report TRUTAKNA exposure by calling 1-833-633-8372. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk IgAN in pregnancy is associated with adverse maternal outcomes, including increased rates of cesarean section, pregnancy-induced hypertension, pre-eclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including stillbirth and low birth weight.

Fetal/Neonatal Adverse Reactions Based on mechanism of action, TRUTAKNA may cause immunosuppression in the in utero exposed infant. The potential clinical impact of TRUTAKNA exposure in infants exposed in utero should be considered. Data Animal Data In pregnant mice, SC administration of atacicept-vymj once every two days (0, 5, 20, and 80 mg/kg) throughout organogenesis from gestation day (GD) 6 to 15 did not result in any adverse effects on embryofetal development at up to 80 mg/kg, approximately 12 times the clinical exposure at the RHD based on area under the concentration curve (AUC).

In pregnant rabbits, SC administration of atacicept-vymj once every two days (0, 5, 20, and 80 mg/kg) throughout organogenesis from GD 6 to 18 resulted in early and late resorptions, reduced number of live fetuses, and decreased mean fetal weight at ≥20 mg/kg, doses that resulted in maternal toxicity (reduced body weight gain). Exposures at these doses were ≥4 times the clinical exposure at the RHD, based on AUC. Embryofetal malformations (enlarged bregmatic fontanella, severe reduction of ossification of parietal or frontal bones, and unossified interparietal bones) were observed at 80 mg/kg (maternally toxic dose), approximately 11 times the clinical exposure at the RHD, based on AUC.

No treatment-related malformations were observed at up to 20 mg/kg, approximately 4 times the clinical exposure at the RHD, based on AUC. In a pre- and post-natal development study in mice, SC administration of atacicept-vymj once every two days (0, 5, 20, or 80 mg/kg) throughout pregnancy and lactation (GD 6 to lactation day 21) did not result in adverse effects on maternal function or development of offspring at up to 80 mg/kg, approximately 12 times the clinical exposure at the RHD based on AUC.

🧒 Pediatric Use 16 words ▾

8.4Pediatric Use The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

🧓 Geriatric Use 50 words ▾

8.5Geriatric Use Clinical studies of TRUTAKNA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adult patients. No clinically meaningful differences in the pharmacokinetics of TRUTAKNA were observed in patients aged 65 and over compared to younger adult patients.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Atacicept-vymj, a BLyS-specific inhibitor and APRIL blocker, is a TACI-Fc fusion glycoprotein that binds B cell activating factor (BAFF) and APRIL with dissociation constants (Kd) of 106 pM and 33 pM, respectively, and reduces BAFF- and APRIL-mediated signaling. BAFF is also known as BlyS. Reduction in BAFF- and APRIL-mediated signaling decreases production of serum galactose deficient IgA1 (Gd-IgA1), which is implicated in the pathophysiology of IgAN.

12.2Pharmacodynamics Immunoglobulins In IgAN patients treated with TRUTAKNA once weekly in the Origin 3 study, serum Gd-IgA1, Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) levels decreased within 4 weeks and these reductions were sustained through Week 36. By Week 36, mean serum levels were reduced from baseline by 68% for Gd-IgA1, 64% for IgA, 36% for IgG, and 75% for IgM.

12.3Pharmacokinetics Absorption Following once weekly SC administration of TRUTAKNA 150 mg in IgAN patients, atacicept-vymj pharmacokinetics increased proportionally over a dose range of 75 to 150 mg. Steady state was achieved after approximately 24 weeks. Following the first SC dose, the maximum atacicept-vymj concentrations were reached approximately 36 hours after atacicept-vymj administration.

Distribution Central and peripheral volume of distribution were 44 L and 61 L, respectively, in patients with IgAN. Metabolism/Elimination No drug metabolism studies have been conducted. Atacicept-vymj is a therapeutic protein that is expected to be catabolized into small peptides and amino acids by general catabolic degradation processes in multiple tissues.

The estimated clearance of atacicept-vymj is

3.2L/day, and the elimination half-life is approximately 40 days in IgAN patients. Specific Populations No clinically significant differences in the pharmacokinetics of atacicept-vymj were observed based on sex, age (18 to 74 years), weight (38.4 to 138 kg), race, and mild to severe renal impairment (eGFR: 22 to 89 mL/min).

12.6Immunogenicity The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of TRUTAKNA. In a pooled analysis of phase 2 and phase 3 clinical data through Week 36 in patients with primary IgAN, 43.2% (60 of 139) of study subjects who were treated with TRUTAKNA once weekly developed ADA.

There were no clinically significant effects of ADA on the pharmacokinetics, pharmacodynamics, safety or effectiveness of TRUTAKNA over the treatment duration of 36 weeks in these studies.

🧬 Mechanism of Action 70 words ▾

12.1Mechanism of Action Atacicept-vymj, a BLyS-specific inhibitor and APRIL blocker, is a TACI-Fc fusion glycoprotein that binds B cell activating factor (BAFF) and APRIL with dissociation constants (Kd) of 106 pM and 33 pM, respectively, and reduces BAFF- and APRIL-mediated signaling. BAFF is also known as BlyS. Reduction in BAFF- and APRIL-mediated signaling decreases production of serum galactose deficient IgA1 (Gd-IgA1), which is implicated in the pathophysiology of IgAN.

📦 How Supplied / Storage and Handling 193 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied TRUTAKNA (atacicept-vymj) injection is a sterile, preservative-free, clear to slightly opalescent, brownish-yellow solution, free of visible particles for subcutaneous administration supplied as a single-dose autoinjector. The autoinjector is not made with natural rubber latex. TRUTAKNA is supplied as follows: Pre-filled autoinjector: Carton contains four 150 mg/mL single-dose autoinjectors: NDC 85052-101-04

16.2Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. If needed, TRUTAKNA autoinjector may be stored at room temperature up to 25°C (77°F), for a single period of 3 days (72 hours). Once TRUTAKNA has been stored at room temperature, it should not be placed back into the refrigerator.

Discard the autoinjector if not used within this 72‑hour period. Do not freeze. Do not shake.

Do not expose to heat.

16.1How Supplied TRUTAKNA (atacicept-vymj) injection is a sterile, preservative-free, clear to slightly opalescent, brownish-yellow solution, free of visible particles for subcutaneous administration supplied as a single-dose autoinjector. The autoinjector is not made with natural rubber latex. TRUTAKNA is supplied as follows: Pre-filled autoinjector: Carton contains four 150 mg/mL single-dose autoinjectors: NDC 85052-101-04

📦 Storage and Handling 82 words ▾

16.2Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. If needed, TRUTAKNA autoinjector may be stored at room temperature up to 25°C (77°F), for a single period of 3 days (72 hours). Once TRUTAKNA has been stored at room temperature, it should not be placed back into the refrigerator.

Discard the autoinjector if not used within this 72‑hour period. Do not freeze. Do not shake.

Do not expose to heat.

📋 Description 168 words ▾

11 DESCRIPTION Atacicept-vymj, a B-lymphocyte stimulator (Blys)-specific inhibitor and A Proliferation Inducing Ligand (APRIL) blocker, is a soluble recombinant fusion glycoprotein consisting of two parts: the extracellular ligand binding portion of the human transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) receptor and the Fc portion of human IgG1 (TACI Fc), which has been modified to reduce Fc receptor-mediated effector functions. Atacicept-vymj is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.

The molecular weight of atacicept-vymj is 73.5 kDa (kilodaltons) based on the homodimeric form of the protein, which is composed of two identical monomers. TRUTAKNA (atacicept-vymj) injection is supplied as a sterile, preservative-free, clear to slightly opalescent, brownish yellow solution for subcutaneous injection. It is supplied in a 1 mL single-dose pre-filled autoinjector with a 27-gauge needle with a needle guard.

Each 1 mL contains 150 mg of atacicept-vymj, 0.82 mg sodium acetate, 79.98 mg trehalose, and Water for Injection. Sodium hydroxide and acetic acid are included to adjust the pH to 5.0.

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Patient Information and Instructions for Use ). Infections Inform patients that TRUTAKNA may decrease the ability of their immune system to fight infections. Advise patients to contact their healthcare provider if they develop signs or symptoms of infection [see Warnings and Precautions ( 5.1 )] Hypersensitivity and other Administration Reactions Advise patients to immediately seek medical attention for any signs and symptoms of hypersensitivity or systemic administration-related reactions.

Inform patients that local injection-site reactions may occur and to report any severe reactions [see Contraindications ( 4 ) and Adverse Reactions ( 6.1 )] . Immunization Recommend that patients complete any required vaccinations prior to initiating treatment with TRUTAKNA. [see Warnings and Precautions ( 5.2 )] . Pregnancy Advise patients who are exposed to TRUTAKNA during pregnancy to contact 1-833-633-8372 [see Use in Specific Populations ( 8.1 )] .

Disposal of Autoinjectors Advise patients to follow disposal procedures in the Instructions for Use. A puncture-resistant container for disposal of needles and syringes should be used. Instruct patients that they will need to follow their community guidelines for the correct way to dispose of their sharps disposal container.

Instruct patients not to recycle their used sharps disposal container. Manufactured by: Vera Therapeutics, Inc. Brisbane, CA 94005 U.S.

License No. 2386 TRUTAKNA™ is a trademark of Vera Therapeutics, Inc © 2026 Vera Therapeutics, Inc.

🧬 Pharmacokinetics 161 words ▾

12.3Pharmacokinetics Absorption Following once weekly SC administration of TRUTAKNA 150 mg in IgAN patients, atacicept-vymj pharmacokinetics increased proportionally over a dose range of 75 to 150 mg. Steady state was achieved after approximately 24 weeks. Following the first SC dose, the maximum atacicept-vymj concentrations were reached approximately 36 hours after atacicept-vymj administration.

Distribution Central and peripheral volume of distribution were 44 L and 61 L, respectively, in patients with IgAN. Metabolism/Elimination No drug metabolism studies have been conducted. Atacicept-vymj is a therapeutic protein that is expected to be catabolized into small peptides and amino acids by general catabolic degradation processes in multiple tissues.

The estimated clearance of atacicept-vymj is

3.2L/day, and the elimination half-life is approximately 40 days in IgAN patients. Specific Populations No clinically significant differences in the pharmacokinetics of atacicept-vymj were observed based on sex, age (18 to 74 years), weight (38.4 to 138 kg), race, and mild to severe renal impairment (eGFR: 22 to 89 mL/min).

🧬 Pharmacodynamics 65 words ▾

12.2Pharmacodynamics Immunoglobulins In IgAN patients treated with TRUTAKNA once weekly in the Origin 3 study, serum Gd-IgA1, Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) levels decreased within 4 weeks and these reductions were sustained through Week 36. By Week 36, mean serum levels were reduced from baseline by 68% for Gd-IgA1, 64% for IgA, 36% for IgG, and 75% for IgM.

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES The effect of TRUTAKNA on proteinuria was evaluated in a randomized, double-blind, placebo controlled study (Origin 3, NCT04716231) in adults with biopsy-proven IgAN, estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m 2 , proteinuria (defined as either a urine protein-to-creatinine ratio [UPCR] based on a 24-hour urine sample ≥1 g/g or total urine protein excretion ≥1.0 g per 24 hours), on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and/or a mineralocorticoid receptor antagonist (MRA).

Patients with other glomerulopathies or those who had been treated with systemic immunosuppressants in the 12 weeks prior to screening were excluded. Patients were randomized (1:1) to receive either TRUTAKNA 150 mg or placebo once a week via SC injection. Rescue immunosuppressive treatment could be initiated per investigator discretion during the trial.

The efficacy analysis included the first 203 patients who reached the Week 36 visit. At baseline, the mean age was 40 years (range: 18 to 72 years), 57% were male, 43% were White, 55% were Asian, <1% were Black, and 15% were from the United States. At baseline, the geometric mean UPCR was 1.5 g/g, mean eGFR was 65 mL/min/1.73 m 2 , and 60% had hematuria based on urine dipstick.

Approximately 62% of patients had a history of hypertension and 8% had a history of type 2 diabetes mellitus. At baseline, nearly all patients were treated with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB), and 53% of patients were on an SGLT2i. No patients received rescue immunosuppressive therapy during the 36-week study period.

The primary efficacy endpoint was the percent reduction in UPCR based on a 24-hour urine sample at Week 36 relative to baseline ( Table 1 ). The mean percent change from baseline in UPCR over time is shown in Figure 1 . Table 1: Percent Reduction in UPCR at Week 36 in Origin 3 a Percent reduction in UPCR was obtained from the geometric mean ratios, where the natural log–transformed ratio to baseline in UPCR (based on 24-hour urine collection) was analyzed using an MMRM adjusted by stable SGLT2i use at baseline, region, baseline eGFR category, and baseline natural log–transformed UPCR.

MMRM analysis included double-blind period data up to Week 36, regardless of treatment discontinuation or initiation of rescue immunosuppressive treatment for IgAN or prohibited therapy; missing values were imputed with jump to reference approach. b The 99% CI for the treatment effect vs. placebo is (24, 55), corresponding to the two-sided significance level of 0.01 for the primary endpoint at the interim analysis. Abbreviations: g/g, gram per gram; CI, confidence interval; N, number of randomized subjects in each group; UPCR, urine protein-to-creatinine ratio; MMRM, Mixed Model for Repeated Measures; eGFR, estimated glomerular filtration rate; IgAN, immunoglobulin A nephropathy.

TRUTAKNA (N=106) Placebo (N=97) Percent reduction in UPCR at Week 36 relative to baseline (95% CI) a 46 7 (38, 53) (-8, 19) TRUTAKNA versus placebo: Percent reduction in UPCR at Week 36 relative to baseline (95% CI) b 42 (29, 52) p value <0.0001 Figure 1: Geometric Mean (95% CI) Percent Change from Baseline in UPCR by Visit in Origin 3 Adjusted percent change relative to baseline in UPCR (sampled from a 24-hour urine collection) with 95% CI reported in the figure were estimated based on the MMRM analysis in Table 1 . “n” represents the number of subjects with observed data for each visit and treatment group.

Abbreviations: CI, confidence interval; MMRM, mixed model repeated measures; UPCR, urine protein-to-creatinine ratio. The treatment effect on UPCR at Week 36 was generally consistent across subgroups including age, sex, race, and baseline disease characteristics (such as baseline eGFR and proteinuria levels). The treatment effect… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 137 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies have been conducted with atacicept-vymj. Mutagenesis Atacicept-vymj was not mutagenic or clastogenic in in vitro Ames, in vitro chromosomal aberration, and in vivo micronucleus assays. Impairment of Fertility No effects on male fertility were observed in mice dosed once every two days for 4 weeks prior to mating and throughout the mating period with SC atacicept-vymj up to 80 mg/kg, at exposures approximately 20 times the clinical exposure at the RHD, based on AUC.

Increased pre- and post-implantation losses and reduced number of live fetuses were observed in female mice dosed with SC atacicept-vymj once every two days from 14 days prior to mating to GD 7 at ≥20 mg/kg, at exposures approximately 4 times the clinical exposure at the RHD, based on AUC.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 134 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies have been conducted with atacicept-vymj. Mutagenesis Atacicept-vymj was not mutagenic or clastogenic in in vitro Ames, in vitro chromosomal aberration, and in vivo micronucleus assays. Impairment of Fertility No effects on male fertility were observed in mice dosed once every two days for 4 weeks prior to mating and throughout the mating period with SC atacicept-vymj up to 80 mg/kg, at exposures approximately 20 times the clinical exposure at the RHD, based on AUC.

Increased pre- and post-implantation losses and reduced number of live fetuses were observed in female mice dosed with SC atacicept-vymj once every two days from 14 days prior to mating to GD 7 at ≥20 mg/kg, at exposures approximately 4 times the clinical exposure at the RHD, based on AUC.

📄 Patient Package Insert ~3 min read ▾

This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 07/2026 PATIENT INFORMATION TRUTAKNA (tru-TAK-nuh) (atacicept-vymj) injection, for subcutaneous use What is TRUTAKNA?

TRUTAKNA is a prescription medicine used to reduce protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), who are at risk of their disease getting worse. It is not known if TRUTAKNA is safe and effective in children. Do not use TRUTAKNA if you: are allergic to atacicept-vymj or any of the ingredients in TRUTAKNA.

See the end of this Patient Information for a complete list of ingredients in TRUTAKNA. Get emergency help if you develop signs and symptoms of an allergic reaction including: breathing problems itching swelling of the face, eyes, lips, tongue, or throat hives dizziness or lightheadedness skin rash Before using TRUTAKNA, tell your healthcare provider about all of your medical conditions, including if you: have or think you have an infection or have infections that keep coming back. have recently received or are scheduled to receive an immunization (vaccine).

TRUTAKNA may affect your immune system response to vaccines and increase your risk of an infection from live vaccines. You should be brought up to date with all vaccines before starting treatment with TRUTAKNA. You should not receive live vaccines within 30 days before starting treatment with TRUTAKNA or during treatment with TRUTAKNA. are pregnant or plan to become pregnant.

It is not known if TRUTAKNA will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with TRUTAKNA. If you become pregnant during treatment with TRUTAKNA, you or your healthcare provider should call 1-833-633-8372. are breastfeeding or plan to breastfeed.

It is not known if TRUTAKNA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you take TRUTAKNA. Tell your healthcare provider about all the medicines you take , including prescription and over the counter medicines, vitamins, and herbal supplements.

Using TRUTAKNA with certain medicines may increase your risk of infections. How should I take TRUTAKNA? See the detailed Instructions for Use that comes with TRUTAKNA for information about how to prepare and inject a dose of TRUTAKNA and how to properly store and throw away (dispose of) used TRUTAKNA autoinjectors .

Use TRUTAKNA exactly as your healthcare provider tells you to. Use TRUTAKNA 1 time each week. TRUTAKNA is given as an injection under the skin (subcutaneous injection).

Inject TRUTAKNA under the skin in the stomach area (abdomen) at least 2 inches away from the belly button (navel), or the front of the thigh. Choose a different site each time you inject TRUTAKNA. If you miss a dose of TRUTAKNA, inject the missed dose as soon as possible then continue TRUTAKNA 1 time each week, starting 1 week after you injected the missed dose What are the possible side effects of TRUTAKNA?

TRUTAKNA can cause serious side effects, including: Immunosuppression and increased risk of infections. TRUTAKNA weakens your immune system, which may increase your risk of infections. Your healthcare provider will check you for signs and symptoms of infections before you start and during treatment with TRUTAKNA.

Tell your healthcare provider right away if you develop any signs and symptoms of infection during treatment with TRUTAKNA including: fever flu-like symptoms chills aches and pains feeling tired warm, red, or painful skin cough The most common side effects of TRUTAKNA include : upper respiratory tract infection and injection site reactions, such as redness, swelling, itching or skin irritation at the injection site. Your healthcare provider may interrupt treatment with TRUTAKNA if you have serious side effects. These are not all the possible side effects of TRUTAKNA.

Call your doctor for medical advice about side effects. You may report side ef… [Excerpted — this section continues on DailyMed.]

📖 Instructions for Use ~3 min read ▾

These Instructions for Use have been approved by the U.S. Food and Drug Administration. LBL-0038, V1.0 Approved: 07/2026 INSTRUCTIONS FOR USE TRUTAKNA ™ (tru-TAK-nuh) (atacicept-vymj) injection, for subcutaneous use 150 mg/mL Single-dose Pre-filled Autoinjector This Instructions for Use contains information on how to inject TRUTAKNA.

Read this Instructions for Use before you use the TRUTAKNA autoinjector and each time you get a refill. There may be new information. Important Information You Need to Know Before Injecting TRUTAKNA For subcutaneous use only (inject under the skin).

Inject TRUTAKNA into the stomach area (abdomen) or thigh only. Each TRUTAKNA autoinjector is for 1-time use only. Do not pull the cap off the TRUTAKNA autoinjector until you are ready to inject.

Do not use the TRUTAKNA autoinjector if it has been dropped or damaged. Do not use the TRUTAKNA autoinjector if the tamper seal on the original packaging is torn or damaged. If the TRUTAKNA autoinjector was accidentally activated, throw away the activated TRUTAKNA autoinjector.

See Step 9 : Throwing away (disposal). Throw away (dispose of) the TRUTAKNA autoinjector right after your injection. See Step 9 : Throwing away (disposal).

The TRUTAKNA autoinjector is not made with natural rubber latex. If you have any questions about injecting TRUTAKNA, call Vera Therapeutics at 1-833-633-8372 or call your healthcare provider. Supplies Needed TRUTAKNA autoinjector Alcohol wipes (not included) Cotton balls or gauze (not included) Adhesive bandage (not included) FDA-cleared sharps disposal container (not included) Storing TRUTAKNA Store TRUTAKNA in the refrigerator between 36°F and 46°F (2°C and 8°C).

Store TRUTAKNA in the original carton until time of use to protect it from light. If needed, TRUTAKNA may be stored at room temperature up to 77°F (25°C) for a single period of 3 days (72 hours). After TRUTAKNA has been stored at room temperature, it should not be placed back into the refrigerator.

Throw away (discard) TRUTAKNA autoinjector if not used within these 3 days (72 hours). Do not freeze TRUTAKNA. Do not shake TRUTAKNA.

Keep TRUTAKNA away from heat. Safely throw away TRUTAKNA that has expired or is no longer needed. Keep the TRUTAKNA autoinjector and all medicines out of the reach of children.

Getting Started 1. Bring the TRUTAKNA autoinjector to room temperature Remove one TRUTAKNA autoinjector from the refrigerator and allow it to sit for 15 to 30 minutes at room temperature between 60°F to 77°F (15°C to 25°C) before injecting. Allowing the TRUTAKNA autoinjector to warm may make the injection more comfortable.

Do not microwave or heat up the TRUTAKNA autoinjector. 2. Check the TRUTAKNA autoinjector Without removing the cap, check the cap for any visible damage.

Check the TRUTAKNA autoinjector for any damage, such as cracks, dents, and leaks. Make sure the name TRUTAKNA is on the label. Check the expiration date.

Check the viewing window. You should see the gray stopper tip on one end of the viewing window. If the viewing window is filled with blue, the TRUTAKNA autoinjector will not work.

Use a new TRUTAKNA autoinjector if the viewing window is blue. Look at the liquid medicine in the viewing window. It should be clear, brownish-yellow and free of particles or cloudiness.

A small bubble inside the liquid medicine is okay. Do not try to remove the bubble. Do not use the TRUTAKNA autoinjector if: There is any damage to the cap or to the autoinjector body.

The expiration date has passed. The liquid medicine is cloudy or has particles. Selecting the Injection Site 3.

Choose the injection site Wash your hands with soap and water. Find a quiet area with a well-lit, clean, and flat work surface. Choose an injection site on the stomach area (abdomen) at least 2-inches away from the belly button (navel), or front of the thigh (See Figure C ).

Choose a different injection site each time you inject TRUTAKNA. Rotating injection sites may help prevent injection site irritati… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 22 words ▾

PRINCIPAL DISPLAY PANEL - NDC 85052-101-04 - Carton Label Carton Label

PRINCIPAL DISPLAY PANEL - NDC 85052-101-01 - Autoinjector Label Autoinjector Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Trutakna (this brand).

Top reported reactions

Blood Immunoglobulin G Decreased3
Bedridden2
Burning Sensation2
Diarrhoea2
Illness2
Inflammation2
Influenza Like Illness2

Age at onset

Elderly1

Reporter sex

8 reports
Male · 33%
Female · 67%

Serious outcomes

Death1
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 3 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Vera Therapeutics, Inc. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Vera Therapeutics, Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.